Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Yanan Kuang"'
Autor:
Jennifer Y. Ge, Shaokun Shu, Mijung Kwon, Bojana Jovanović, Katherine Murphy, Anushree Gulvady, Anne Fassl, Anne Trinh, Yanan Kuang, Grace A. Heavey, Adrienne Luoma, Cloud Paweletz, Aaron R. Thorner, Kai W. Wucherpfennig, Jun Qi, Myles Brown, Piotr Sicinski, Thomas O. McDonald, David Pellman, Franziska Michor, Kornelia Polyak
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast canc
Externí odkaz:
https://doaj.org/article/c6750e9707894301940edb49bbf81051
Autor:
Jasneet Kaur Khalsa, Justin Cha, Filippo Utro, Aishath Naeem, Ishwarya Murali, Yanan Kuang, Kevin A. Vasquez, Liang Li, Svitlana Tyekucheva, Stacey M. Fernandes, Lauren Veronese, Romain Guieze, Binu Kandathilparambil Sasi, Zixu Wang, John-Hanson Machado, Harrison P. Bai, Maryam Alasfour, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, Cloud P. Paweletz, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Publikováno v:
Blood Journal.
Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a382fac79b98504ad575401318eced3
https://doi.org/10.1182/blood.2022016600
https://doi.org/10.1182/blood.2022016600
Autor:
Pasi A. Jänne, Stephen Wang, Sujuan Guo, Jiannan Guo, Paul T. Kirschmeier, Jens Köhler, Zihan Wei, Fangxin Hong, Pratik R. Chopade, Prafulla C. Gokhale, Christie J. Lau, Kshiti H. Dholakia, Nam Doo Kim, Taebo Sim, Luke J. Taus, Yanan Kuang, Cloud P. Paweletz, Magda Bahcall
Application of Bliss independence to test for synergy effect of TKI combination treatment in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4903139a78bc221e2202f3b12db12a51
https://doi.org/10.1158/1535-7163.22521927.v1
https://doi.org/10.1158/1535-7163.22521927.v1
Autor:
Geoffrey R. Oxnard, Pasi A. Jänne, Lynette M. Sholl, Michael T. Jaklitsch, Mark M. Awad, Christine A. Lydon, Nam Doo Kim, Adrian G. Sacher, Yanan Kuang, Ryan S. Alden, Jyoti D. Patel, Cloud P. Paweletz, Taebo Sim, Magda Bahcall
Supplementary Table S2 shows type I and II MET kinase inhibitors and key trials studying their activity lung cancer populations enriched for MET-dependence.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15259866f9abcdf86d7e410f5beeefec
https://doi.org/10.1158/2159-8290.22531684.v1
https://doi.org/10.1158/2159-8290.22531684.v1
Autor:
Geoffrey R. Oxnard, Pasi A. Jänne, Lynette M. Sholl, Michael T. Jaklitsch, Mark M. Awad, Christine A. Lydon, Nam Doo Kim, Adrian G. Sacher, Yanan Kuang, Ryan S. Alden, Jyoti D. Patel, Cloud P. Paweletz, Taebo Sim, Magda Bahcall
Supplementary Figure S2 shows expression of D1228V mutation in PC9 cells as confirmed by RT-PCR and cDNA sequencing.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f1895aa1d85644a36ffd00d28504bd3
https://doi.org/10.1158/2159-8290.22531693
https://doi.org/10.1158/2159-8290.22531693
Autor:
Pasi A. Jänne, Stephen Wang, Sujuan Guo, Jiannan Guo, Paul T. Kirschmeier, Jens Köhler, Zihan Wei, Fangxin Hong, Pratik R. Chopade, Prafulla C. Gokhale, Christie J. Lau, Kshiti H. Dholakia, Nam Doo Kim, Taebo Sim, Luke J. Taus, Yanan Kuang, Cloud P. Paweletz, Magda Bahcall
MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb636b4d303925dcf3349ce844b41a8
https://doi.org/10.1158/1535-7163.c.6543231.v1
https://doi.org/10.1158/1535-7163.c.6543231.v1
Autor:
Pasi A. Jänne, Stephen Wang, Sujuan Guo, Jiannan Guo, Paul T. Kirschmeier, Jens Köhler, Zihan Wei, Fangxin Hong, Pratik R. Chopade, Prafulla C. Gokhale, Christie J. Lau, Kshiti H. Dholakia, Nam Doo Kim, Taebo Sim, Luke J. Taus, Yanan Kuang, Cloud P. Paweletz, Magda Bahcall
Supplementary Figures S1-3; Supplementary Tables S1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53186772e45cde82b5f37f176dc5fdfc
https://doi.org/10.1158/1535-7163.22521930.v1
https://doi.org/10.1158/1535-7163.22521930.v1
Autor:
Geoffrey R. Oxnard, Pasi A. Jänne, Lynette M. Sholl, Michael T. Jaklitsch, Mark M. Awad, Christine A. Lydon, Nam Doo Kim, Adrian G. Sacher, Yanan Kuang, Ryan S. Alden, Jyoti D. Patel, Cloud P. Paweletz, Taebo Sim, Magda Bahcall
Supplementary methods, including croplet digital PCR for MET D1228V; molecular docking study; Molecular Dynamics Simulations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66178e86266b7f57556717acb447e4b9
https://doi.org/10.1158/2159-8290.22531690
https://doi.org/10.1158/2159-8290.22531690
Autor:
Geoffrey R. Oxnard, Pasi A. Jänne, Lynette M. Sholl, Michael T. Jaklitsch, Mark M. Awad, Christine A. Lydon, Nam Doo Kim, Adrian G. Sacher, Yanan Kuang, Ryan S. Alden, Jyoti D. Patel, Cloud P. Paweletz, Taebo Sim, Magda Bahcall
Supplementary Figure Legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d0595d6657535e5c5ceb1a1d16ded0
https://doi.org/10.1158/2159-8290.22531699
https://doi.org/10.1158/2159-8290.22531699
Autor:
Geoffrey R. Oxnard, Pasi A. Jänne, Lynette M. Sholl, Michael T. Jaklitsch, Mark M. Awad, Christine A. Lydon, Nam Doo Kim, Adrian G. Sacher, Yanan Kuang, Ryan S. Alden, Jyoti D. Patel, Cloud P. Paweletz, Taebo Sim, Magda Bahcall
Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non–small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f2e5d3751318d33e0581bb264f2fbd
https://doi.org/10.1158/2159-8290.c.6546440
https://doi.org/10.1158/2159-8290.c.6546440